Management of Moderate to Severe Plaque Psoriasis
نویسنده
چکیده
cancer, arthritis, hypertension, heart disease, diabetes, and depression (Rapp 1999). In the last decade, a new understanding about the pathophysiology of psoriasis has resulted in the development of a new class of agents for these patients: targeted biologic therapy. These novel treatments target specific immunologic processes involved in the genesis of this disease, providing significant clinical benefit to psoriasis sufferers. The American Academy of Dermatology (AAD) Consensus Statement places biologic therapies among the currently approved systemic treatments for patients with widespread disease.
منابع مشابه
Moderate and severe plaque psoriasis: cost-of-illness study in Italy
Psoriasis is a chronic inflammatory, immune-mediated skin disorder that affects 1.5-1.8 million people in Italy. The most common form of the disease is chronic plaque psoriasis, affecting about 90% of psoriasis patients, with about 20%-30% of them suffering from a moderate or severe condition. Little information is available about the economic impact of psoriasis in European countries. The prim...
متن کاملPotential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
BACKGROUND Psoriasis is a debilitating autoimmune skin disease that affects 2%-3% of the world's population. Patients with moderate-to-severe plaque psoriasis suffer from a decreased quality of life as well as comorbidities. Newer biological agents have been shown to be more effective than traditional therapies. In this article, we assess the potential role of ixekizumab, an anti-interleukin (I...
متن کاملTopical Turmeric Microemulgel in the Management of Plaque Psoriasis; A Clinical Evaluation
Psoriasis is an autoimmune and recurrent chronic inflammatory skin disease. About 1-3% of the world wide populations are affected. The characteristic features are hyperprolifration of keratinocytes leading to redness, thickening and scaling of epidermis followed with itching and appearance of the lesions which in most cases bother the patients medically and psychologically. Psoriasis is symptom...
متن کاملTopical Turmeric Microemulgel in the Management of Plaque Psoriasis; A Clinical Evaluation
Psoriasis is an autoimmune and recurrent chronic inflammatory skin disease. About 1-3% of the world wide populations are affected. The characteristic features are hyperprolifration of keratinocytes leading to redness, thickening and scaling of epidermis followed with itching and appearance of the lesions which in most cases bother the patients medically and psychologically. Psoriasis is symptom...
متن کاملClinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions
Psoriasis is a common, chronic, immune mediated, inflammatory disease of skin characterized by red patches enclosed with white scales and affects 2-3% of people in the world. Topical therapy, phototherapy, and systemic therapy were employed for management of disease from many last decades. However, long term uses of these agents are associated with unwanted effects and toxicities. Recently, Ito...
متن کاملA prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate to-severe chronic plaque-type psoriasis: the Psoriasis Infiximab vs. Etanercept Comparison Evaluation (PIECE) study
There are no direct comparison data between infliximab and entanercept in the treatment of psoriasis. This study was a mult icenter, randomised control trial done in the Netherlands to compare the efficacy, outcome of etanercept vs. infliximab in the management of moderate to severe chronic plaque psoriasis. Patients (age 1875 years old) with Psoriasis Area and Severity Index (PASI) ≥10 and/or ...
متن کامل